Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Terns Pharmaceuticals, Inc. - Common Stock (NQ:TERN)

52.80 -0.06 (-0.11%)
Streaming Delayed Price Updated: 10:43 AM EDT, Mar 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,004,444
Open 52.84
Bid (Size) 52.80 (22,700)
Ask (Size) 52.81 (41,100)
Prev. Close 52.86
Today's Range 52.80 - 52.96
52wk Range 1.865 - 52.98
Shares Outstanding 61,071,897
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ARM Makes Its Move While Wall Street Watches the Strait ↗
Via Chartmill
News headline image
Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. - TERN
From Kahn Swick & Foti, LLC
Via Business Wire

Performance

YTD
+31.6%
+31.6%
1 Month
+29.2%
+29.2%
3 Month
+24.6%
+24.6%
6 Month
+570.9%
+570.9%
1 Year
+1490.4%
+1490.4%

More News

Read More
News headline image
The Strategic Renaissance: Why 2026 is the Year of the Takeover Tailwind
Via MarketMinute
Topics Artificial Intelligence Economy
VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals ↗
Via Stocktwits
News headline image
The $6.7 Billion Pivot: A Deep Dive into Terns Pharmaceuticals (TERN) and the Merck Acquisition
Via Finterra
Topics Initial Public Offering Intellectual Property World Trade
News headline image
TERN Stock Alert: Halper Sadeh LLC is Investigating Whether Terns Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? ↗
Via The Motley Fool
News headline image
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain ↗
Via The Motley Fool
News headline image
Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Fund Sold $8 Million of Terns Stock Last Quarter, but Here's Why It Still Seems Very Bullish ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally ↗
Via The Motley Fool
News headline image
This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally ↗
Via The Motley Fool
News headline image
Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Announces Pricing of Upsized $650 Million Public Offering
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Announces Proposed Public Offering
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Terns Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Terns Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Terns Pharmaceuticals, Inc. - Common Stock trade on?
Terns Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Terns Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Terns Pharmaceuticals, Inc. - Common Stock is TERN on the Nasdaq Stock Market
What is the current price of Terns Pharmaceuticals, Inc. - Common Stock?
The current price of Terns Pharmaceuticals, Inc. - Common Stock is 52.80
When was Terns Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Terns Pharmaceuticals, Inc. - Common Stock was at 03/26/26 10:43 AM ET
What is the market capitalization of Terns Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Terns Pharmaceuticals, Inc. - Common Stock is 3.22B
How many shares of Terns Pharmaceuticals, Inc. - Common Stock are outstanding?
Terns Pharmaceuticals, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.